Beta-bisabolol is a sesquiterpene alcohol found in selected wood and leaf oils, including Hiba Japanese cedarwood records in the AromaForge archive. Compared with alpha-bisabolol, the literature is much thinner but still real: recent work supports clear identity and stereospecific biosynthesis, while preclinical studies report in vitro anti-inflammatory effects and a separate mosquito-control paper describes strong larvicidal activity for the closely related epi-beta-bisabolol stereoisomer rather than beta-bisabolol itself. That makes beta-bisabolol a valid archive constituent with cautious, preclinical-only activity coverage.
Chemical identity and composition
PubChem identifies beta-bisabolol as C15H26O. In the archive's Hiba Japanese cedarwood oil record, beta-bisabolol is a minor sesquiterpene alcohol at 2.1%. A 2024 Valeriana jatamansi study also clarified the stereospecific plant biosynthesis of beta-bisabolol through a dedicated sesquiterpene synthase.
Aroma and practical use
- Use the recorded soft, woody, floral, sweet descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A cotton-gin-trash paper reported that purified beta-bisabolol reduced multiple inflammatory mediators in vitro at non-toxic concentrations.
The abstract reports dose-dependent inhibition of NO, PGE2, TNF-alpha, IL-6, and IL-8, with activity described as similar to alpha-bisabolol at the compared concentration.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2024 plant-biochemistry study identified VjBisS as a beta-bisabolol synthase responsible for stereospecific biosynthesis in Valeriana jatamansi.
The paper used in vitro and in vivo enzyme assays plus mutagenesis-oriented follow-up to define catalytic specificity.
This experimental finding does not establish benefit, dose or safety in people using this blend.
Archive oil context confirms beta-bisabolol as a real but minor constituent in Hiba Japanese cedarwood oil.
The Hiba oil record cites a directly readable composition paper with beta-bisabolol at 2.1%.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
No constituent-specific public cosmetic safety monograph, IFRA dermal maximum, or dedicated phototoxicity review for isolated beta-bisabolol was located in this pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Because the accessible activity literature is mostly cellular and stereochemistry can be confusing across beta-bisabolol and epi-beta-bisabolol records, benefit-facing copy should stay conservative.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
dose_dependent_reduction_of_inflammatory_mediators
In LPS-stimulated RAW264.7 macrophages and fibroblast-linked assays, beta-bisabolol reduced nitric oxide, PGE2, TNF-alpha, IL-6, and IL-8 at non-toxic concentrations.
This experimental finding does not establish benefit, dose or safety in people using this blend.
stereospecific_terpene_synthase_biosynthesis
The VjBisS enzyme from Valeriana jatamansi was reported to catalyze stereospecific biosynthesis of beta-bisabolol and helped define residues important for catalytic specificity.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (7)
- This pass did not verify a human clinical study of isolated beta-bisabolol.
- The public literature is much thinner than for alpha-bisabolol, and some nearby papers instead concern epi-beta-bisabolol or mixed essential oils.
- The CIR Safety Assessment of Bisabolol (2015 re-review) covers the INCI ingredient 'Bisabolol' under CAS numbers that are predominantly (-)-alpha-bisabolol and does not list CAS 15352-77-9; its 1% leave-on use conclusion and penetration-enhancer finding are documented for the INCI/CAS family as a whole but are not confirmed as applying specifically to the pure beta stereoisomer, so dermal_limit_pct and penetration_enhancer remain unverified for beta-bisabolol specifically rather than guessed.
- No IFRA Standard specific to beta-bisabolol was located in this pass.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.
- Some findings lack a directly linked source; treat those entries as unverified research notes.